TargetBeta
AKT1
AKT serine/threonine kinase 1 · also RAC, PKB, PRKBA, AKT · Pleckstrin homology domain containing
2 programs in company-led studies act on AKT1, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| capivasertibrule | AstraZeneca | phase 3 | 239 running | AKT2, AKT3 | ChEMBL |
| AKT1 E17K Inhibitor ATV-1601rule | Atavistik Bio | phase 2 | 22 running | – | NCIt |
Conditions their studies are in
- Triple Negative Breast Neoplasms, 2 programs
- Breast Neoplasms, 1 program
- Hematologic Neoplasms, 1 program
- Prostatic Neoplasms, 1 program
- Telangiectasia, Hereditary Hemorrhagic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 1, 2027capivasertib · AstraZeneca · phase 3 · NCT04862663
- Dec 2027AKT1 E17K Inhibitor ATV-1601 · Atavistik Bio · phase 2 · NCT07601425
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.